大麻素及其在精神疾病中的治疗应用 .

IF 8.3 2区 医学 Q1 Medicine Dialogues in Clinical Neuroscience Pub Date : 2020-09-01 DOI:10.31887/DCNS.2020.22.3/pfadda
Maria Scherma, Anna Lisa Muntoni, Gernot Riedel, Walter Fratta, Paola Fadda
{"title":"大麻素及其在精神疾病中的治疗应用 .","authors":"Maria Scherma, Anna Lisa Muntoni, Gernot Riedel, Walter Fratta, Paola Fadda","doi":"10.31887/DCNS.2020.22.3/pfadda","DOIUrl":null,"url":null,"abstract":"<p><p>Mental disorders represent a significant public health burden worldwide due to their high prevalence, chronically disabling nature, and substantial impact on quality of life. Despite growing knowledge of the pathological mechanisms that underlie the development of these disorders, a high percentage of patients do not respond to first-line clinical treatments; thus, there is a strong need for alternative therapeutic approaches. During the past half-century, after the identification of the endocannabinoid system and its role in multiple physiological processes, both natural and synthetic cannabinoids have attracted considerable interest as putative medications in pathological conditions such as, but not exclusive to, mental disorders. Here, we provide a summary of cannabinoid effects in support of possible therapeutic applications for major depression, bipolar disorder, anxiety, posttraumatic stress disorder, and schizophrenia. Considering this evidence, highlighted benefits and risks of cannabinoid use in the management of these illnesses require further experimental study.\u2029.</p>","PeriodicalId":54343,"journal":{"name":"Dialogues in Clinical Neuroscience","volume":"22 3","pages":"271-279"},"PeriodicalIF":8.3000,"publicationDate":"2020-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/da/0e/DialoguesClinNeurosci-22-271.PMC7605020.pdf","citationCount":"0","resultStr":"{\"title\":\"Cannabinoids and their therapeutic applications in mental disorders\\u2029.\",\"authors\":\"Maria Scherma, Anna Lisa Muntoni, Gernot Riedel, Walter Fratta, Paola Fadda\",\"doi\":\"10.31887/DCNS.2020.22.3/pfadda\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>Mental disorders represent a significant public health burden worldwide due to their high prevalence, chronically disabling nature, and substantial impact on quality of life. Despite growing knowledge of the pathological mechanisms that underlie the development of these disorders, a high percentage of patients do not respond to first-line clinical treatments; thus, there is a strong need for alternative therapeutic approaches. During the past half-century, after the identification of the endocannabinoid system and its role in multiple physiological processes, both natural and synthetic cannabinoids have attracted considerable interest as putative medications in pathological conditions such as, but not exclusive to, mental disorders. Here, we provide a summary of cannabinoid effects in support of possible therapeutic applications for major depression, bipolar disorder, anxiety, posttraumatic stress disorder, and schizophrenia. Considering this evidence, highlighted benefits and risks of cannabinoid use in the management of these illnesses require further experimental study.\\u2029.</p>\",\"PeriodicalId\":54343,\"journal\":{\"name\":\"Dialogues in Clinical Neuroscience\",\"volume\":\"22 3\",\"pages\":\"271-279\"},\"PeriodicalIF\":8.3000,\"publicationDate\":\"2020-09-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/da/0e/DialoguesClinNeurosci-22-271.PMC7605020.pdf\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Dialogues in Clinical Neuroscience\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.31887/DCNS.2020.22.3/pfadda\",\"RegionNum\":2,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"Medicine\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Dialogues in Clinical Neuroscience","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.31887/DCNS.2020.22.3/pfadda","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 0

摘要

由于精神障碍的高发病率、长期致残性以及对生活质量的严重影响,精神障碍已成为全球公共卫生的重大负担。尽管人们对这些疾病的病理机制有了越来越多的了解,但仍有很高比例的患者对一线临床治疗无效;因此,人们亟需其他治疗方法。在过去的半个世纪中,在发现了内源性大麻素系统及其在多种生理过程中的作用后,天然和合成大麻素作为治疗精神障碍等病症的药物引起了人们的极大兴趣。在此,我们总结了大麻素的作用,以支持对重度抑郁症、躁郁症、焦虑症、创伤后应激障碍和精神分裂症的可能治疗应用。考虑到这些证据,需要对使用大麻素治疗这些疾病的益处和风险进行进一步的实验研究。.
本文章由计算机程序翻译,如有差异,请以英文原文为准。
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
Cannabinoids and their therapeutic applications in mental disorders
.

Mental disorders represent a significant public health burden worldwide due to their high prevalence, chronically disabling nature, and substantial impact on quality of life. Despite growing knowledge of the pathological mechanisms that underlie the development of these disorders, a high percentage of patients do not respond to first-line clinical treatments; thus, there is a strong need for alternative therapeutic approaches. During the past half-century, after the identification of the endocannabinoid system and its role in multiple physiological processes, both natural and synthetic cannabinoids have attracted considerable interest as putative medications in pathological conditions such as, but not exclusive to, mental disorders. Here, we provide a summary of cannabinoid effects in support of possible therapeutic applications for major depression, bipolar disorder, anxiety, posttraumatic stress disorder, and schizophrenia. Considering this evidence, highlighted benefits and risks of cannabinoid use in the management of these illnesses require further experimental study.
.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Dialogues in Clinical Neuroscience
Dialogues in Clinical Neuroscience Medicine-Psychiatry and Mental Health
CiteScore
19.30
自引率
1.20%
发文量
1
期刊介绍: Dialogues in Clinical Neuroscience (DCNS) endeavors to bridge the gap between clinical neuropsychiatry and the neurosciences by offering state-of-the-art information and original insights into pertinent clinical, biological, and therapeutic aspects. As an open access journal, DCNS ensures accessibility to its content for all interested parties. Each issue is curated to include expert reviews, original articles, and brief reports, carefully selected to offer a comprehensive understanding of the evolving landscape in clinical neuroscience. Join us in advancing knowledge and fostering dialogue in this dynamic field.
期刊最新文献
A global neuronal workspace model of functional neurological disorders. Microcephaly type 22 and autism spectrum disorder: A case report and review of literature. The impact of testosterone-lowering medication on recidivism in individuals convicted of sexual offenses. Predictive values of pre-treatment brain age models to rTMS effects in neurocognitive disorder with depression: Secondary analysis of a randomised sham-controlled clinical trial. Should dietary restrictions be imposed on Alzheimer's Disease patients affected by type 2 diabetes?
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1